Table 1 Demographic and treatment characteristics of adult survivors of childhood cancer (including glioma survivors and all cancer survivors) and siblings, divided by neurofibromatosis type 1 status.
Glioma survivors | All survivors | ||||
|---|---|---|---|---|---|
with NF1 N (%) | without NF1 N (%) | with NF1 N (%) | without NF1 N (%) | Siblings N (%) | |
All participants | 147 | 2629 | 176 | 22,316 | 5 051 |
Sex | |||||
Male | 67 (46%) | 1382 (53%) | 83 (49%) | 11,905 (53%) | 2408 (48%) |
Female | 80 (54%) | 1247 (47%) | 93 (51%) | 10,411 (47%) | 2643 (52%) |
Race/ethnicity | |||||
Non-Hispanic White | 126 (86%) | 2209 (84%) | 151 (85%) | 18,345 (83%) | 4370 (87%) |
Non-Hispanic Black | 7 (5%) | 136 (5%) | 7 (4%) | 1385 (6%) | 149 (3%) |
Hispanic | 8 (5%) | 174 (7%) | 11 (7%) | 1614 (7%) | 214 (4%) |
Other | 6 (4%) | 110 (4%) | 7 (4%) | 972 (4%) | 318 (6%) |
Age at diagnosis | |||||
<1 year | 5 (3%) | 141 (5%) | 13 (7%) | 1708 (7%) | |
1–3 years | 48 (33%) | 545 (21%) | 57 (33%) | 5484 (23%) | |
4–7 years | 43 (29%) | 702 (27%) | 46 (27%) | 4905 (26%) | |
8–10 years | 22 (15%) | 400 (15%) | 24 (13%) | 2407 (14%) | |
11–14 years | 19 (13%) | 525 (20%) | 22 (12%) | 3944 (18%) | |
15–20 years | 10 (7%) | 316 (12%) | 14 (8%) | 3868 (12%) | |
Decade of diagnosis | |||||
1970–1979 | 7 (5%) | 512 (19%) | 11 (6%) | 6322 (22%) | |
1980–1989 | 37 (25%) | 954 (36%) | 48 (28%) | 9055 (37%) | |
1990–1999 | 103 (70%) | 1163 (44%) | 117 (66%) | 6939 (41%) | |
Diagnosis | |||||
ALL | 0 (0%) | 0 (0%) | 3 (5%) | 6145 (5%) | |
AML | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Other leukemia | 0 (0%) | 0 (0%) | 1 (0.6%) | 302 (0.6%) | |
Glioma | 147 (100%) | 2629 (100%) | 147 (81%) | 2629 (81%) | |
Medulloblastoma, PNET | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Hogdkin lymphoma | 0 (0%) | 0 (0%) | 1 (0.6%) | 2995 (0.6%) | |
Non-Hodgkin lymphoma | 0 (0%) | 0 (0%) | 1 (0.6%) | 1986 (0.6%) | |
Kidney tumors | 0 (0%) | 0 (0%) | 4 (2%) | 2155 (2%) | |
Neuroblastoma | 0 (0%) | 0 (0%) | 6 (3%) | 1845 (3%) | |
Soft tissue sarcoma | 0 (0%) | 0 (0%) | 9 (5%) | 1697 (5%) | |
Ewing sarcoma | 0 (0%) | 0 (0%) | 1 (0.6%) | 713 (0.6%) | |
Osteosarcoma | 0 (0%) | 0 (0%) | 2 (1%) | 1203 (1%) | |
Other bone tumor | 0 (0%) | 0 (0%) | 1 (0.6%) | 97 (0.6%) | |
CNS radiation dose | |||||
None | 89 (67%) | 1391 (59%) | 113 (70%) | 14,522 (61%) | |
>0 to <20 Gy | 0 (0%) | 7 (0%) | 2 (3%) | 1851 (2%) | |
20 to <30 Gy | 1 (1%) | 4 (0%) | 1 (1%) | 1579 (1%) | |
30 to <50 Gy | 6 (5%) | 134 (6%) | 7 (4%) | 589 (6%) | |
≥50 Gy | 37 (28%) | 811 (35%) | 37 (22%) | 1310 (30%) | |
Chemotherapy exposure | |||||
Vinca alkyloid | 45 (32%) | 402 (17%) | 62 (39%) | 14,617 (28%) | |
Platinum | 36 (26%) | 257 (11%) | 42 (24%) | 1975 (12%) | |
Alkylating agent | 12 (9%) | 261 (11%) | 27 (19%) | 9468 (20%) | |
Anthracycline | 0 (0%) | 6 (0%) | 14 (11%) | 9758 (10%) | |
Antimetabolite | 7 (5%) | 133 (5%) | 14 (11%) | 9009 (12%) | |
Steroid | 5 (4%) | 196 (8%) | 11 (8%) | 9538 (13%) | |
Epipodophyllotoxin | 6 (4%) | 88 (4%) | 11 (9%) | 3248 (7%) | |
IT methotrexate | 0 (0%) | 5 (0%) | 4 (5%) | 6936 (6%) | |
IV methotrexate | 1 (1%) | 9 (0%) | 5 (4%) | 4922 (5%) | |
Other | 1 (1%) | 25 (1%) | 1 (1%) | 170 (1%) | |
